PerkinElmer Immunoassay Helps NIH NCATS Team Identify Therapeutic Compounds Capable of Disrupting the SARS-CoV-2 Spike Protein/ACE2 Interaction
Findings shared on open data portal to help in global pursuit of drug repurposing candidates for COVID-19 WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 20, 2020– PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that a research team at the National Center for Advancing Translational Sciences (NCATS), an arm of the National... Read more